NEW YORK (GenomeWeb News) – Intrexon today announced an agreement to acquire adult stem cell technology firm Medistem for about $26 million.

Based in San Diego, Medistem develops endometrial regenerative cells, which are universal donor adult stem cells that stimulate new blood vessel formation. ERCs can generate different tissues such as heart, brain, pancreas, liver, bone, cartilage, and lung, and Intrexon plans to use its synthetic biology platforms to "engineer a diverse array of cell-based therapeutic candidates using Medistem's multipotent ERCs," it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.